For example, VATG-027 (Figure 6, 27) and VATG-032 (Figure 6, 28) have therapeutic potential to sensitize oncogenic BRAF V600E mutant melanoma tumor to vemurafenib by lysosomal deacidification and disruption of autophagosome (Goodall et al., 2014). The gene discussed is BRAF; the disease is melanoma.